Literature DB >> 867981

Agranulocytosis and antithyroid drugs.

M H Rosove.   

Abstract

Propylthiouracil and methimazole are used widely in the treatment of hyperthyroid disorders. The most important complication of the use of these drugs is depression of the neutrophilic granulocyte count. Granulocytopenia occurs in about 4 percent and agranulocytosis occurs in about 0.3 percent of treated patients. Although this depression of the granulocyte count is reversible after the drug is discontinued, serious infection frequently accompanies agranulocytosis and accounts for almost all deaths related to the drugs. It is important to be aware of the clinical features of granulocytopenic reactions due to antithyroid drugs.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 867981      PMCID: PMC1237580     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  35 in total

1.  Thiouracil in the Treatment of Thyrotoxicosis.

Authors:  A Grainger; D A Gregson; H S Pemberton
Journal:  Br Med J       Date:  1945-09-15

2.  THIOURACIL. ITS ABSORPTION, DISTRIBUTION, AND EXCRETION.

Authors:  R H Williams; G A Kay; B J Jandorf
Journal:  J Clin Invest       Date:  1944-09       Impact factor: 14.808

3.  THE EFFECT OF THIOURACIL ON TISSUE OXIDASE.

Authors:  K E Paschkis; A Cantarow; A E Rakoff; E K Tillson
Journal:  Science       Date:  1945-09-28       Impact factor: 47.728

4.  Antagonistic Action of Uracil, Thiouracil, and Thiourea on Reticulocyte Ripening.

Authors:  A Nizet
Journal:  Science       Date:  1952-03-14       Impact factor: 47.728

5.  Observations on the use of propylthiouracil in hyperthyroidism with especial reference to long-term treatment.

Authors:  E S WING; S P ASPER
Journal:  Bull Johns Hopkins Hosp       Date:  1952-03

6.  Propylthiouracil-induced agranulocytosis, toxic hepatitis, and death.

Authors:  A R COLWELL; D E SANDO; S J LANG
Journal:  J Am Med Assoc       Date:  1952-02-23

7.  Thiouracil in the Treatment of Thyrotoxicosis , Including a Case of Fatal Agranulocytosis.

Authors:  E Lozinski; J Siminovitch
Journal:  Can Med Assoc J       Date:  1944-11       Impact factor: 8.262

8.  Death due to agranulocytosis induced by methimazole therapy.

Authors:  N W SPECHT; E J BOEHME
Journal:  J Am Med Assoc       Date:  1952-07-12

9.  Therapeutic studies in hyperthyroidism; methimazole.

Authors:  H H STONE; D W PETIT; P STARR
Journal:  J Clin Endocrinol Metab       Date:  1952-07       Impact factor: 5.958

10.  Treatment of hyperthyroidism with 1-methyl-2-mercaptoimidazole.

Authors:  W S REVENO; H ROSENBAUM
Journal:  J Am Med Assoc       Date:  1950-08-19
View more
  7 in total

1.  Polymyositis after propylthiouracil treatment for hyperthyroidism.

Authors:  W J Shergy; D S Caldwell
Journal:  Ann Rheum Dis       Date:  1988-04       Impact factor: 19.103

Review 2.  Drug-induced agranulocytosis.

Authors:  H Heimpel
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

Review 3.  Adverse effects of thyroid hormone preparations and antithyroid drugs.

Authors:  L Bartalena; F Bogazzi; E Martino
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

Review 4.  Adverse immunologic effects of antithyroid drugs.

Authors:  S S Wing; I G Fantus
Journal:  CMAJ       Date:  1987-01-15       Impact factor: 8.262

Review 5.  Antithyroid drug-induced agranulocytosis: clinical experience with ten patients treated at one institution and review of the literature.

Authors:  M Meyer-Gessner; G Benker; S Lederbogen; T Olbricht; D Reinwein
Journal:  J Endocrinol Invest       Date:  1994-01       Impact factor: 4.256

6.  Antithyroid drugs induced agranulocytosis and multiple myeloma: case report and general considerations.

Authors:  R Dănciulescu Miulescu; M Carşote; R Trifănescu; D Ferechide; C Poiană
Journal:  J Med Life       Date:  2013-09-25

7.  The calcium-phosphate balance, modulation of thyroid autoimmune processes and other adverse effects connected with thyroid arterial embolization.

Authors:  Grzegorz Kaminski; Andrzej Jaroszuk; Ariadna Zybek; Krzysztof Brzozowski; Piotr Piasecki; Piotr Ziecina; Marek Ruchala
Journal:  Endocrine       Date:  2013-10-22       Impact factor: 3.633

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.